Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis

Thrombosis Research

Volumn 133, Issue 4, 2014, Pages 667-670

  Treliński, Jacek ^a   Misiewicz, Małgorzata ^a   Robak, Marta ^a   Smolewski, Piotr ^a   Chojnowski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Multiple myeloma; ROTEM; Thromboelastometry

Indexed keywords

BLOOD CLOTTING FACTOR 8; D DIMER; HEMOGLOBIN; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ERYTHROCYTE; FEASIBILITY STUDY; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; ROTATION THROMBOELASTOMETRY; THROMBOCYTE COUNT; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; VERY ELDERLY; BLOOD; PHYSIOLOGY; PROCEDURES;

AGED; AGED, 80 AND OVER; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THROMBELASTOGRAPHY;

EID: 84896115681     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.01.011     Document Type: Article

References (36)

1. G. Cesarman-Maus, E. Braggio, and R. Fonseca Thrombosis in multiple myeloma (MM) Hematology 17 2012 177 180
2. F.W. Leebeek, M.J. Kruip, and P. Sonneveld Risk and management of thrombosis in multiple myeloma Thromb Res 129 2012 88 92
3. E.J. Libourel, P. Sonneveld, B. van der Holt, M.P. de Maat, and F.W. Leebeek High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study Blood 116 2010 22 26
4. S.Y. Kristinsson Thrombosis in multiple myeloma Hematology Am Soc Hematol Educ Program 2010 2010 437 444
5. S.Y. Kristinsson, T.R. Fears, G. Gridley, I. Turesson, U.H. Mellqvist, and M. Björkholm et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma Blood 112 2008 3582 3586
6. S.Y. Kristinsson, R.M. Pfeiffer, M. Björkholm, L.R. Goldin, S. Schulman, and C. Blimark et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study Blood 115 2010 4991 4998
7. K. Osman, R. Comenzo, and S.V. Rajkumar Deep venous thrombosis and thalidomide therapy for multiple myeloma N Engl J Med 344 2001 1951 1952
8. R. Baz, L. Li, K. Kottke Marchant, G. Srkalovic, B. McGowan, and E. Yiannaki et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma Mayo Clin Proc 80 2005 1568 1574
9. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, P.R. Greipp Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 2006 431 436
10. M. Robak, J. Treliński, and K. Chojnowski Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma Med Oncol 29 2012 3574 3580
11. A.M. van Marion, J.J. Auwerda, M.C. Minnema, R. van Oosterom, J. Adelmeijer, and P.G. de Groot et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis Thromb Haemost 94 2005 1341 1343
12. A.M. van Marion, J.J. Auwerda, T. Lisman, P. Sonneveld, M.P. de Maat, and H.M. Lokhorst et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens Leuk Res 32 2008 1078 1084
13. F. Elice, L. Fink, G. Tricot, B. Barlogie, and M. Zangari Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism Br J Haematol 134 2006 399 405
14. G. Srkalovic, M.G. Cameron, L. Rybicki, S.R. Deitcher, K. Kattke Marchant, and M.A. Hussein Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease Cancer 101 2004 558 566
15. A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano, and F. Patriarca et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial J Clin Oncol 29 2011 986 993
16. A. Larocca, F. Cavallo, S. Bringhen, F. Di Raimondo, A. Falanga, and A. Evangelista et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 2012 933 939
17. S.Y. Kristinsson, R.M. Pfeiffer, M. Björkholm, S. Schulman, and O. Landgren Thrombosis is associated with inferior survival in multiple myeloma Haematologica 97 2012 1603 1607
18. R.J. Luddington Thrombelastography/thromboelastometry Clin Lab Med 27 2005 81 90
19. T. Lang, A. Bauters, S.L. Braun, B. Pötzsch, K.W. von Pape, and H.J. Kolde et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry Blood Coagul Fibrinolysis 16 2005 301 310
20. T. Lang, and M. von Depka Possibilities and limitations of thrombelastometry/-graphy Hamostaseologie 26 2006 20 29
21. S. Dunkley, and L. Gaudry Thalidomide causes platelet activation, which can be abrogated by aspirin J Thromb Haemost 5 2007 1323 1325
22. R. Niesvizky, D. Martínez Baños, J. Jalbrzikowski, P. Christos, J. Furst, and M. De Sancho et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma Leuk Lymphoma 48 2007 2330 2337
23. F. Avcu, A.U. Ural, T. Cetin, and O. Nevruz Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro Thromb Res 121 2008 567 571
24. M. Zangari, J. Guerrero, F. Cavallo, H.K. Prasad, D. Esseltine, and L. Fink Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma Haematologica 93 2008 953 954
25. C. Solomon, N. Rahe-Meyer, H. Schöchl, M. Ranucci, and K. Görlinger Effect of haematocrit on fibrin-based clot firmness in the FIBTEM test Blood Transfus 11 2013 412 418
26. A. Dear, S.O. Brennan, M.J. Sheat, J.M. Faed, and P.M. George Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain Haematologica 92 2007 e111 e117
27. S. Sugai IgA pyroglobulin, hyperviscosity syndrome and coagulation abnormality in a patient with multiple myeloma Blood 39 1972 224 237
28. M.J. O'Kane, G.B. Wisdom, Z.R. Desai, and G.P. Archbold Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin J Clin Pathol 47 1994 266 268
29. D.A. Gabriel, L.A. Smith, J.D. Folds, L. Davis, and S.E. Cancelosi The influence of immunoglobulin (IgG) on the assembly of fibrin gels J Lab Clin Med 101 1983 545 552
30. R. Kotlín, A. Sobotková, T. Riedel, P. Salaj, J. Suttnar, and Z. Reicheltová et al. Acquired dysfibrinogenemia secondary to multiple myeloma Acta Haematol 120 2008 75 81
31. B.M. Iselin, P.F. Willimann, B. Seifert, M. Casutt, T. Bombeli, and M.P. Zalunardo et al. Isolated reduction of haematocrit does not compromise in vitro blood coagulation Br J Anaesth 87 2001 246 249
32. L. Spiezia, C. Radu, P. Marchioro, D. Bertini, V. Rossetto, and M. Castelli et al. Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients Thromb Haemost 100 2008 1106 1110
33. M. Nagler, S. Kathriner, L.M. Bachmann, and W.A. Wuillemin Impact of changes in haematocrit level and platelet count on thromboelastometry parameters Thromb Res 131 2013 249 253
34. J.P. Collet, D. Park, C. Lesty, J. Soria, C. Soria, and G. Montalescot et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy Arterioscler Thromb Vasc Biol 20 2000 1354 1361
35. J.W. Weisel Structure of fibrin: impact on clot stability J Thromb Haemost 5 2007 116 124
36. J.W. Weisel, and R.I. Litvinov The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate Cardiovasc Hematol Agents Med Chem 6 2008 161 180